TRT and Polycythemia (Erythrocytosis): Why Your Hematocrit Rises and How to Manage It

Elevated hematocrit—the percentage of red blood cells in your blood—is the most frequently reported adverse event in testosterone clinical trials. It occurs in a majority of men on TRT to some degree, and when left unchecked it can thicken your blood enough to meaningfully elevate cardiovascular risk.

That doesn't mean TRT has to stop. What it means is that hematocrit needs active monitoring and, for some men, deliberate management. Men on TRT who understand their hematocrit trajectory and have a management plan with their prescribing clinician stay on therapy longer and with better outcomes.

What Is Erythrocytosis and When Does It Matter?

Erythrocytosis (often called polycythemia in clinical practice, though they're not technically identical) means your body is producing too many red blood cells. The standard threshold clinicians use is a hematocrit above 54% in men. Normal male hematocrit typically runs 40-50%, though individual reference ranges vary slightly by lab.

A 2024/2025 retrospective study of 247 patients on TRT found that 23% reached hematocrit above 50% and 5% exceeded the critical 54% threshold during therapy. But the full picture is broader: 57% of patients reached hematocrit above 46% at some point, showing that some degree of RBC elevation is almost universal on TRT. The study, published in Frontiers in Endocrinology, tracked patients for a median of nearly 3 years.

The clinical threshold of 54% matters because that's where the Endocrine Society guidelines recommend reducing the testosterone dose or stopping therapy temporarily—blood viscosity at that level significantly increases stroke and clot risk.

Why Testosterone Raises Hematocrit

Testosterone stimulates red blood cell production through three well-documented mechanisms:

1. EPO stimulation. Exogenous testosterone increases serum erythropoietin (EPO), the hormone your kidneys use to signal bone marrow to make more red blood cells. When testosterone levels spike—such as after a large intramuscular injection—the EPO response is proportionally amplified.

2. Hepcidin suppression. Testosterone suppresses hepcidin, the liver hormone that regulates iron absorption. Lower hepcidin means more iron is absorbed from food and released from storage, giving your bone marrow abundant raw material for making hemoglobin and red blood cells. This pathway is considered a primary driver of testosterone-induced erythrocytosis.

3. Direct bone marrow action. Testosterone acts directly on bone marrow progenitor cells to increase red blood cell production, independent of EPO signaling. Research also suggests a secondary pathway through insulin-like growth factor 1 (IGF-1).

The net effect: more iron available, stronger signaling, and direct stimulation at the marrow level. It's a three-pronged push toward red cell overproduction.

Who Is at Highest Risk

The Frontiers in Endocrinology study identified two independent risk factors that significantly predict who develops treatment-induced erythrocytosis:

Higher baseline BMI. For each additional BMI unit, the odds of erythrocytosis increased by 13-15%. The researchers theorize that higher visceral fat leads to increased testosterone-to-estradiol conversion and insulin resistance, both of which may independently stimulate red blood cell synthesis.

Elevated baseline hematocrit. Men who started TRT with hematocrit above 41% were nearly 5 times more likely (OR 4.71) to reach elevated hematocrit levels (≥46%) during therapy compared to men who started lower. If you're already near the top of the normal range before beginning TRT, you'll need closer monitoring.

Other contributors that appear in the literature but had mixed statistical significance in the multivariate analysis include active smoking (which causes relative polycythemia through carbon monoxide binding), untreated sleep apnea (intermittent hypoxia drives secondary erythropoiesis), and high-altitude living. These factors compound the testosterone-driven effect.

The Formulation Factor

Not all TRT formulations carry the same erythrocytosis risk. Injectable testosterone—particularly long-acting esters like testosterone undecanoate—tends to produce larger hematocrit increases than topical gels.

The explanation appears to be tied to dosing patterns. Large intramuscular or subcutaneous injections create acute testosterone spikes. Those spikes trigger disproportionate EPO surges and hepcidin drops, essentially driving red cell production in bursts. This is sometimes called "bolus dosing" in the literature.

More frequent, smaller injections—sometimes called micro-dosing—maintain more stable serum testosterone levels across the week. Stable levels mean no dramatic EPO surges, which typically translates to more manageable hematocrit trajectories. Some clinicians also find that switching from injections to gels helps patients whose hematocrit cannot be controlled through dose adjustment alone.

How It's Monitored

Hematocrit and hemoglobin are part of the standard complete blood count (CBC) blood test. TRT blood work protocols typically call for CBC monitoring at baseline, then at 3, 6, and 12 months after starting TRT, and annually thereafter.

The Frontiers in Endocrinology study found that only 46% of patients who developed elevated hematocrit did so within the first year. More than half of erythrocytosis cases appeared after 12 months of therapy. This is important: men who normalize their hematocrit at the one-year check shouldn't assume the risk is over. Annual monitoring needs to continue for the duration of therapy.

Key lab markers to track:

• Hematocrit (HCT): Primary monitoring metric. Normal male range is approximately 40-50%. Above 54% triggers clinical intervention.
• Hemoglobin (Hb): Closely correlated with HCT. Normal male range is approximately 36-44 g/L.
• RDW (red cell distribution width): Should not fall below 10.2%, which could indicate microcytic anemia despite a high hematocrit reading.
• MCH (mean corpuscular hemoglobin): Low values may warrant follow-up testing for iron, B12, and folate status.

Management Options When Hematocrit Climbs

When hematocrit approaches or exceeds 54%, clinicians typically consider several interventions:

Dose reduction or frequency adjustment. The first-line approach per Endocrine Society guidelines. Reducing the testosterone dose (or switching to more frequent, smaller injections) often brings hematocrit back into range. This preserves TRT benefits while lowering the erythropoietic stimulus.

Temporary discontinuation. If hematocrit is well above 54% or the patient is symptomatic, clinicians may pause TRT until hematocrit drifts down, then restart at a lower dose.

Therapeutic venesection (phlebotomy). Medically supervised blood removal to reduce hematocrit. A 2024 systematic review in Endocrine Connections examined whether phlebotomy could be avoided through TRT dose modification alone, but found that while dose reduction works for many patients, some require venesection to stay on effective testosterone therapy. This is a common and well-established procedure.

Blood donation. TRT does not disqualify you from donating blood. Some men on TRT who are otherwise healthy manage borderline-elevated hematocrit through regular blood donation, which safely lowers HCT while contributing to the blood supply. Always discuss this approach with your prescribing clinician first.

Formulation switching. Switching from injectable testosterone to topical gel can reduce erythrocytosis risk because gels provide a steadier, more physiological testosterone delivery profile without the injection-related peaks.

The Iron Paradox

There's a paradoxical situation that some TRT patients encounter: high hematocrit alongside iron deficiency. Because testosterone suppresses hepcidin and the bone marrow is aggressively using iron to build red blood cells, patients can be erythrocytic (high HCT) but simultaneously depleted of iron stores. This can manifest as fatigue, brain fog, or restless legs—symptoms that might otherwise be attributed to poorly dosed TRT.

If you're on TRT and experience fatigue despite stable testosterone levels and acceptable hematocrit, ask your clinician to check ferritin and iron panels alongside your standard CBC.

What You Can Do

Patients on TRT have some degree of control over their hematocrit trajectory:

Stay hydrated. Dehydration causes relative polycythemia—your hematocrit reads artificially high because plasma volume is low. Consistent hydration helps ensure your lab results reflect true red cell mass.

Address sleep apnea. Untreated obstructive sleep apnea compounds erythrocytosis risk through intermittent hypoxia, which independently stimulates EPO production. Treating sleep apnea (with CPAP or other interventions) can reduce this additional drive.

Don't smoke. Smoking both reduces plasma volume (relative effect) and increases carboxyhemoglobin, which triggers true erythropoiesis. It compounds the TRT effect from multiple angles.

Report symptoms. Headaches, dizziness, visual disturbances, and a ruddy complexion can signal elevated hematocrit. These warrant a CBC check outside the standard schedule.

When Erythrocytosis May Signal Something Else

If your hematocrit is dramatically elevated (well above 54%) despite appropriate TRT dosing, or if it rises very rapidly, your clinician should rule out causes unrelated to testosterone. The differential diagnosis includes Polycythemia Vera—a distinct bone marrow disorder caused by a JAK2 gene mutation—kidney disease or cysts, EPO-secreting tumors, chronic lung disease, and prolonged high-altitude exposure. These are true secondary or primary erythrocytosis and need treatment beyond adjusting testosterone.

Polycythemia vera is a myeloproliferative neoplasm and is fundamentally different from testosterone-induced erythrocytosis. Your clinician can distinguish between them using EPO levels, JAK2 mutation testing, and additional hematological markers.

The Bottom Line

Elevated hematocrit on TRT is expected, monitorable, and manageable. The key steps are: get a baseline CBC before starting, check hematocrit at 3/6/12 months and annually after, work with your prescribing clinician on dose adjustments if levels climb, and don't ignore the fact that risk factors like higher BMI, smoking, and sleep apnea compound the effect. For most men, proactive hematocrit management means staying on TRT longer without compromising cardiovascular health.

This article is for informational purposes only and does not constitute medical advice. Hematocrit management decisions should always be made with your prescribing clinician, who can evaluate your full clinical picture and adjust treatment accordingly.